CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
WORCESTER, Mass., April 05, 2016 -- Nemucore Medical Innovations, Inc., a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers, announced today that Timothy P. Coleman, President and Chief Executive Officer, will present a corporate overview and update at the Needham & Company’s 15th Annual Healthcare Conference on April 12-13, 2016 in New York City. The Nemucore presentation will take place at 09:20 AM on Wednesday, April 13, 2016.
About Nemucore Medical Innovations, Inc.
Nemucore Medical Innovations, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to the development of therapies targeting multi-drug resistant cancers with a special emphasis on highly lethal women’s cancers. Nemucore's most advanced candidate NMI-900, a potential "best-in-class" therapeutic for the treatment of ovarian cancer, is expected to begin a Phase 2b clinical trial in late-2016. Two additional candidates are anticipated to enter clinical trial development later in 2017, targeting a variety of difficult-to-treat oncology indications, including breast, non-small cell lung cancer (NSCLC), myelodysplastic syndrome (MDS) and other cancers. For more information, please visit our website at www.Nemucore.com.
Contacts: Tim Coleman (investors) Nemucore Medical Innovations (508) 762-1017 BCC Partners (media) Karen L. Bergman (650) 575-1509 [email protected] Jen LaVin (207) 360-0473 [email protected]
